[Asia Economy Reporter Jang Hyowon] Kyungnam Pharmaceutical is showing strong performance. It is interpreted to be influenced by news of shortages of cold medicine and antipyretics due to a surge in COVID-19 patients in China.
As of 10:39 AM on the 2nd, Kyungnam Pharmaceutical is trading at 3,090 KRW, up 15.11% compared to the previous day.
Recently, as China has eased its COVID-19 restrictions and a 'twindemic' of influenza and COVID-19 is occurring domestically, concerns about shortages of cold medicine are growing. In particular, cases of stockpiling cold medicine for smuggling into China have been reported.
Kyungnam Pharmaceutical is primarily engaged in the manufacturing and wholesale and retail of pharmaceuticals and raw materials for pharmaceuticals, as well as the manufacturing and sales of health functional foods. It manufactures and sells various cold medicines, analgesics, antipyretics, and anti-inflammatory drugs, including Lemona, its founding product athlete's foot medicine PM, and sore throat treatment Minoleptroki.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
